Predicted the P2RX7 rs3751143 polymorphism is associated with cancer risk: a meta-analysis and systematic review

• Published in: Bioscience reports 2021-02, Vol.41 (2)
• Main Authors: Wang, Bi-Jun, Chen, Jun-Yi, Guan, Yu, Liu, Da-Chao, Cao, Zi-Chuan, Kong, Jin, Wu, Zheng-Sheng, Wu, Wen-Yong
• Format: Article
• Language: English
• Subjects: Cancer; Cell Migration, Adhesion & Morphology; Chi-square test; Ethnicity; Gene Expression & Regulation; Genetic Predisposition to Disease; Health risks; Heterogeneity; Humans; Ion channels; Leukemia; Liver cancer; Meta-analysis; Mutation; Neoplasms - genetics; Polymerase chain reaction; Polymorphism; Polymorphism, Genetic; Purine P2X receptors; Receptors, Purinergic P2X7 - genetics; Risk analysis; Systematic review; Thyroid cancer; White people
• ISSN: 0144-8463; 1573-4935
• DOI: 10.1042/BSR20193877

Both meta-analyses and systematic reviews were used to assess the relationship between purinergic receptor P2X ligand-gated ion channel 7 (P2RX7) rs3751143 polymorphism and the risk of cancer. The data used in this research were collected from Google Scholar, Web of Science, CNKI, and Wan Fang Data databases. The final retrieval ended on 22 February 2019. The strength of correlation was assessed using odds ratios and 95% confidence intervals. Based on the heterogeneity test results, fixed-effect (Mantel-Haenszel) or random-effects (DerSimonian-Laird) models were selected to summarise the collective effects. Eight separate studies containing 1462 cancer cases and 3037 controls were enrolled. Overall, there was no significant association between P2RX7 rs3751143 polymorphism and the risk of cancer in the allelic, homozygous, heterozygous, dominant, or recessive models. Our meta-analysis indicates that there is no significant association between P2RX7 rs3751143 polymorphism and the risk of cancer in the allelic, homozygous, heterozygous, dominant, and recessive models.